469 related articles for article (PubMed ID: 30665272)
21. Comparison of Rural vs Urban Direct-to-Physician Commercial Promotion of Medications for Treating Opioid Use Disorder.
Nguyen T; Andraka-Christou B; Simon K; Bradford WD
JAMA Netw Open; 2019 Dec; 2(12):e1916520. PubMed ID: 31790568
[TBL] [Abstract][Full Text] [Related]
22. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
Rhee TG; Rosenheck RA
Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
[TBL] [Abstract][Full Text] [Related]
23. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
[No Abstract] [Full Text] [Related]
24. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
[TBL] [Abstract][Full Text] [Related]
25. The case for a medication first approach to the treatment of opioid use disorder.
Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
[No Abstract] [Full Text] [Related]
26. Prescribing patterns of buprenorphine waivered physicians.
Thomas CP; Doyle E; Kreiner PW; Jones CM; Dubenitz J; Horan A; Stein BD
Drug Alcohol Depend; 2017 Dec; 181():213-218. PubMed ID: 29096292
[TBL] [Abstract][Full Text] [Related]
27. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
[TBL] [Abstract][Full Text] [Related]
28. Spillover of Medicaid Expansion to Prescribing of Opioid Use Disorder Medications in Medicare Part D.
Abraham AJ; Lawler EC; Harris SJ; Bagwell Adams G; Bradford WD
Psychiatr Serv; 2022 Apr; 73(4):418-424. PubMed ID: 34407628
[TBL] [Abstract][Full Text] [Related]
29. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
30. Barriers to Buprenorphine Expansion in Ohio: A Time-Elapsed Qualitative Study.
Molfenter T; Fitzgerald M; Jacobson N; McCarty D; Quanbeck A; Zehner M
J Psychoactive Drugs; 2019; 51(3):272-279. PubMed ID: 30732542
[TBL] [Abstract][Full Text] [Related]
31. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
32. Buprenorphine Prescribing and Challenges Faced Among National Health Service Corps Clinicians.
Rowan K; Shah SV; Binns S; Murphy E; Satorius J; Ghobadi A; Krauss D; Robbins C; Schoebel V; Knudson A; Kepley H;
JAMA Netw Open; 2024 May; 7(5):e2411742. PubMed ID: 38758556
[TBL] [Abstract][Full Text] [Related]
33. Disparities in Access to Opioid Treatment Programs and Office-Based Buprenorphine Treatment Across the Rural-Urban and Area Deprivation Continua: A US Nationwide Small Area Analysis.
Amiri S; McDonell MG; Denney JT; Buchwald D; Amram O
Value Health; 2021 Feb; 24(2):188-195. PubMed ID: 33518025
[TBL] [Abstract][Full Text] [Related]
34. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
35. Update on pharmacotherapy for treatment of opioid use disorder.
Ayanga D; Shorter D; Kosten TR
Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
[TBL] [Abstract][Full Text] [Related]
36. Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency.
Paiva TJ; Wightman RS; St John K; Nitenson AZ; Onyejekwe C; Hallowell BD
J Subst Use Addict Treat; 2024 Jul; 162():209382. PubMed ID: 38677597
[TBL] [Abstract][Full Text] [Related]
37. Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems.
Boudreau DM; Lapham G; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Campbell CI; Rossom RC; Binswanger IA; Yarborough BJ; Arnsten JH; Cunningham CO; Glass JE; Murphy MT; Zare M; Hechter RC; Ahmedani B; Braciszewski JM; Horigian VE; Szapocznik J; Samet JH; Saxon AJ; Schwartz RP; Bradley KA
J Subst Abuse Treat; 2020 Mar; 112S():41-48. PubMed ID: 32220410
[TBL] [Abstract][Full Text] [Related]
38. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
39. Help Is on the Way: Medicare Coverage of Opioid Treatment Programs.
Felix C; Sharfstein JM; Olsen Y
J Am Geriatr Soc; 2020 Mar; 68(3):637-640. PubMed ID: 31825528
[TBL] [Abstract][Full Text] [Related]
40. Primary care physicians' preparedness to treat opioid use disorder in the United States: A cross-sectional survey.
Foti K; Heyward J; Tajanlangit M; Meek K; Jones C; Kolodny A; Alexander GC
Drug Alcohol Depend; 2021 Aug; 225():108811. PubMed ID: 34175786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
